ClinicalTrials.Veeva

Menu
B

Bhakti Vedanta Hospital and Research Institute | Thane, India

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lasmiditan
LY573144
Lorlatinib
PF-07850327
Cetuximab
Tirzepatide
ARV-471
LY3298176
Encorafenib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small ce...

Active, not recruiting
Non-Small-Cell Lung
Carcinoma
Drug: Lorlatinib

Trial sponsors

Lilly logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems